Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.

Chunhong Hu,Sixuan Wu,Renfang Deng,Yuanqiang Wu,Yue Pan,Long Shu,Fang Wu

Annals of Oncology（2022）

Cited 2|Views1

No score

Abstract

Radiotherapy with continued TKIs is effective for EGFR-mutated NSCLC with oligoprogression, and it should be conducted as soon as possible. T790M+ patients have higher sensitivity to radiotherapy, and patients with good performance status and stereotactic body radiation therapy have better PFS2 and OS.

Translated text

Key words

EGFR-mutated non-small-cell lung cancer,oligoprogression,radiotherapy,survival,tyrosine kinase inhibitors

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined